Clene Inc
CLNN
Company Profile
Business description
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Contact
6550 South Millrock Drive
Suite G50
Salt Lake CityUT84121
USAT: +1 801 676-9695
Sector
Consumer Defensive
Stock type
Defensive
Industry
Packaged Foods
Fiscal Year End
31 December 2026
Employees
76
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
Everything you need to know on last weeks earnings results
stocks
ASX player rallies on small guidance upgrade
Our fair value is maintained despite investor enthusiasm.
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.80 | 66.60 | -0.72% |
| CAC 40 | 8,311.74 | 28.82 | -0.35% |
| DAX 40 | 24,914.88 | 62.19 | 0.25% |
| Dow JONES (US) | 49,500.93 | 48.95 | 0.10% |
| FTSE 100 | 10,446.35 | 43.91 | 0.42% |
| HKSE | 26,567.12 | 465.42 | -1.72% |
| NASDAQ | 22,546.67 | 50.48 | -0.22% |
| Nikkei 225 | 56,941.97 | 697.87 | -1.21% |
| NZX 50 Index | 13,198.18 | 333.30 | -2.46% |
| S&P 500 | 6,836.17 | 3.41 | 0.05% |
| S&P/ASX 200 | 8,917.60 | 55.30 | -0.62% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |